The Complement System and Preeclampsia

Jean F. Regal, Richard Burwick, Sherry D. Fleming

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Purpose of Review: Preeclampsia affects 3–4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. Recent Findings: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Summary: Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.

Original languageEnglish (US)
Article number87
JournalCurrent Hypertension Reports
Volume19
Issue number11
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Pre-Eclampsia
Complement Membrane Attack Complex
Pregnancy
Mothers
Complement Activation
Therapeutics
Fetal Development
Proteinuria
Homeostasis
Animal Models
Hypertension
Safety
Research

Keywords

  • Complement system
  • Innate immunity
  • Placenta
  • Placental ischemia
  • Preeclampsia
  • Pregnancy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

The Complement System and Preeclampsia. / Regal, Jean F.; Burwick, Richard; Fleming, Sherry D.

In: Current Hypertension Reports, Vol. 19, No. 11, 87, 01.11.2017.

Research output: Contribution to journalReview article

Regal, Jean F. ; Burwick, Richard ; Fleming, Sherry D. / The Complement System and Preeclampsia. In: Current Hypertension Reports. 2017 ; Vol. 19, No. 11.
@article{32e727dfb62147038930f6a11086e74c,
title = "The Complement System and Preeclampsia",
abstract = "Purpose of Review: Preeclampsia affects 3–4{\%} of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. Recent Findings: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Summary: Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.",
keywords = "Complement system, Innate immunity, Placenta, Placental ischemia, Preeclampsia, Pregnancy",
author = "Regal, {Jean F.} and Richard Burwick and Fleming, {Sherry D.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s11906-017-0784-4",
language = "English (US)",
volume = "19",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "11",

}

TY - JOUR

T1 - The Complement System and Preeclampsia

AU - Regal, Jean F.

AU - Burwick, Richard

AU - Fleming, Sherry D.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose of Review: Preeclampsia affects 3–4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. Recent Findings: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Summary: Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.

AB - Purpose of Review: Preeclampsia affects 3–4% of pregnancies with few treatment options to reduce maternal and fetal harm. Recent evidence that targeting the complement system may be an effective therapeutic strategy in prevention or treatment of preeclampsia will be reviewed. Recent Findings: Studies in humans confirm the safety and efficacy of C5 blockade in complement-mediated disorders of pregnancy, including preeclampsia. Animal models mimic the placental abnormalities and/or the maternal symptoms which characterize preeclampsia. These models in mouse and rat have defined a role for complement and its regulators in placental dysfunction, hypertension, proteinuria, endothelial dysfunction, fetal growth restriction, and angiogenic imbalance, thus informing future human studies. Summary: Targeting excessive complement activation, particularly the terminal complement complex (C5b-9) and C5a may be an effective strategy to prolong pregnancy in women with preeclampsia. Continued research is needed to identify the initiator(s) of activation, the pathways involved, and the key component(s) in the pathophysiology to allow development of safe and effective therapeutics to target complement without compromising its role in homeostasis and host defense.

KW - Complement system

KW - Innate immunity

KW - Placenta

KW - Placental ischemia

KW - Preeclampsia

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85032032155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032032155&partnerID=8YFLogxK

U2 - 10.1007/s11906-017-0784-4

DO - 10.1007/s11906-017-0784-4

M3 - Review article

C2 - 29046976

AN - SCOPUS:85032032155

VL - 19

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 11

M1 - 87

ER -